Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders

 Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders

Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders

Shots:

  • Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M and will take care of development of all products
  • The focus of the agreement is to build a joint venture i.e  Anthos Therapeutics developing anti-thrombotic therapies for patients with high-risk cardiovascular disorders
  • Novartis’ MAA868 is a mAb with anti- Factor XI / XIa involved in prevention of thrombotic disorders with minimal or no bleeding risk

Click here to read full press release/ article | Ref: Anthos Therapeutics | Image: Anthos Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post